Controlled-release formulations for Parasitic disease

Previous research has established a link between parasitosis, cancer, and co-morbid bacterial and viral infections. However, managing parasitic disease is more complex than commonly believed. While broad-spectrum anti-protozoan and anti-helminthic treatments are often used, they do not always fully resolve infections. This is because parasitic effectiveness is influenced not just by drug dosage but also by reproductive cycles, maturation processes, and overall population load. This preprint explores therapeutic alternatives aimed at addressing high parasitic burdens, with a focus on minimizing adverse effects and mitigating pancreatitis, hepatic, pulmonary, and gastrointestinal inflammation.